The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanders, M. E.
Right arrow Articles by Joiner, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanders, M. E.
Right arrow Articles by Joiner, K. A.

The Journal of Immunology, Vol 138, Issue 7 2095-2099, Copyright © 1987 by American Association of Immunologists


ARTICLES

Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus

ME Sanders, EL Alexander, CL Koski, MM Frank and KA Joiner

We have examined cerebrospinal fluid (CSF) and serum from patients with Sjogren's syndrome (SS) and systemic lupus erythematosus (SLE) for evidence of activation of the terminal pathway of complement. Fluid phase terminal complement complexes (SC5b-9), quantitated by ELISA, were detected in the CSF of 14 of 16 patients with SS and focal central nervous system (CNS) disease. Five of six SS patients without focal CNS disease but with psychiatric disease or cognitive dysfunction had detectable CSF SC5b-9, whereas two other SS patients without focal CNS or neuropsychiatric disease had no detectable CSF SC5b-9. Six of seven patients with SLE or SLE overlap syndrome with CNS involvement had CSF SC5b-9, whereas two patients with SLE without CNS involvement had no CSF SC5b-9. A subset of SS and SLE patients with CNS disease had SC5b-9 detected in CSF but not in serum. SC5b-9 was generally absent from the CSF of patients with noninflammatory CNS diseases. These findings demonstrate intrathecal activation of terminal complement in patients with CNS SS or CNS SLE, and suggest a role for terminal complement activation in the pathophysiology of CNS involvement in both SS and SLE.


This article has been cited by other articles:


Home page
Ann Rheum DisHome page
F C Soliotis, C P Mavragani, and H M Moutsopoulos
Central nervous system involvement in Sjogren's syndrome
Ann Rheum Dis, June 1, 2004; 63(6): 616 - 620.
[Full Text]


Home page
LupusHome page
A Jonsen, A A Bengtsson, O Nived, B Ryberg, L Truedsson, L Ronnblom, G V Alm, and G Sturfelt
The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles
Lupus, November 1, 2003; 12(11): 846 - 850.
[Abstract] [PDF]


Home page
BloodHome page
A. Dobrina, M. Pausa, F. Fischetti, R. Bulla, E. Vecile, E. Ferrero, A. Mantovani, and F. Tedesco
Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo
Blood, January 1, 2002; 99(1): 185 - 192.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
F. Tedesco, M. Pausa, E. Nardon, M. Introna, A. Mantovani, and A. Dobrina
The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity
J. Exp. Med., May 5, 1997; 185(9): 1619 - 1628.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
J. M. Porcel and D. Vergani
Review: Complement and Lupus: Old Concepts and New Directions
Lupus, December 1, 1992; 1(6): 343 - 349.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.